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Background: Previously, we had shown that persons infected with human T-cell lymphoma leukemia virus 1 or 2
(HTLV-1 or 2) had an increased prevalence of antibodies to a peptide in the Pol protein of the retrovirus HERV-K10,
homologous to a peptide in HTLV gp21 envelope protein. The prevalence rate was higher in those with myelopathy vs.
non-myelopathy. We have now extended our observations to a cohort restricted to North America in whom the
diagnosis of HTLV myelopathy was rigorously confirmed to also test for reactivity to another HERV-K10 peptide
homologous to the HTLV p24 Gag protein.
Methods: Sera from 100 volunteer blood donors (VBD), 53 patients with large granular lymphocytic leukemia
(LGLL), 74 subjects with HTLV-1 or 2 infection (58 non-myelopathy and 16 myelopathy) and 83 patients with multiple
sclerosis (MS) were evaluated in ELISA assays using the above peptides.
Results: The HTLV myelopathy patients had a statistically significant increased prevalence of antibodies to both
HERV-K10 peptides (87.5%) vs. the VBD (0%), LGLL patients (0%), MS patients (4.8%), and the HTLV positive
non-myelopathy subjects (5.2%).
Conclusion: The data suggest that immuno-cross-reactivity to HERV-K10 peptides and/or transactivation of HERV-K10
expression by the HTLV Tax protein may be involved in the pathogenesis of HTLV-associated myelopathy/tropical spastic
paraparesis and spastic ataxia.Introduction
In addition to causing T-cell malignancies, both human
T-cell lymphoma/leukemia viruses 1 and 2 (HTLV-1 and
HTLV-2) are known to cause myelopathy (HAM) in a
minority of infected individuals [1-6]. The complete
pathogeneses of these chronic, clinically variable, but
sometimes severe, life threatening neurologic disorders
are not completely understood. However, compared to
asymptomatic HTLV infected individuals, patients with
HAM have a higher HTLV proviral DNA load, higher
rates of HTLV virus production and higher titers of anti-
HTLV antibodies and cytotoxic T-cells [7]. Early in the
disease, areas of central nervous system involvement show
high numbers of polyclonal HTLV infected T-lymphocytes
and an intense polyclonal uninfected cellular immunologic
response [7-12]. HTLV-1 tends to primarily affect the* Correspondence: poieszb@upstate.edu
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stated.thoracic spinal cord and is characterized by progressive
spastic paraparesis, while HTLV-2 is skewed toward the
cerebellum and is characterized by ataxia and usually a
milder clinical course [6].
In previous studies we had determined that, although
only 8% of patients with large granular lymphocytic
leukemia (LGLL) were infected with HTLV-2, almost
half the patients had antibodies to HTLV p24 Gag and
gp21 Env proteins [13]. None of these patients were in-
fected with HTLV-1, HTLV-3, HTLV-4, or bovine leukemia
virus. The seroreactivity to the HTLV gp21 Env protein
was mapped to an eight amino acid peptide (Figure 1). The
only other life form or human amino acid sequence in
the available data bases with homology to both HTLV
p24 Gag and the relevant eight amino acid sequence in
HTLV gp21 Env was the endogenous human retrovirus
HERV-K10 (Figure 1). Accordingly, we tested volunteer
blood donors (VBD), LGLL patients and HTLV-1 or
HTLV-2 infected individuals, some of whom had myelop-
athy, for antibodies to a peptide in HERV-K10 Pol thatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Figure 1 Alignment of amino acid sequences homologous to HTLV-1 BA21 Env peptide (A) and HTLV-1 p24 Gag peptide (B).
Corresponding areas of conservation in HTLV-2 Env and HERV-K10 Pol or HTLV-2 p24 Gag and HERV-K10 Gag are indicated by the (•) symbol.
Amino acid changes are as shown. The underlined peptide in HTLV-1 Env had been previously mapped to be the target of anti-HTLV-1 p21 Env
seroreactivity in LGLL patients. The underlined peptide in HERV-K10 Pol and that shown for HERV-K10 Gag were used in the studies described
herein. The GenBank accession numbers for various sequences are: HTLV-1 Env AAA96674; HTLV-2 Env AAZ16506; HERV-K10 Pol P10266; HTLV-1
Gag AAA85325; HTLV-2 Gag P14077, and HERV-K10 P87889.
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there was a slight, statistically significant increased preva-
lence of anti-HERV-K10 Pol peptide antibodies in the
LGLL group vs VBD, the more interesting observations
were that the HTLV infected population had a statistically
significant higher prevalence of antibodies to HERV-K10
Pol peptide than the VBD, and that this prevalence was
significantly skewed to those patients with myelopathy.
Herein, to obviate against any cross-reactivity secondary
to polyconal gammopathies that are known to be preva-
lent in more underdeveloped parts of the world, we inves-
tigated these observations further in a cohort of subjects
from the continental United States and Canada. Also,
we restricted the study to those in whom the diagnosis
of HTLV myelopathy was rigorously confirmed. In addition
to testing for antibodies to the aforementioned, HERV-K10
Pol peptide, we also tested for antibodies to a HERV-K10
Gag peptide which is homologous to HTLV p24 Gag pro-
tein (Figure 1).
We also did molecular studies involving HERV-K113
and HERV-K115, which are members of the HERV-K10
family [14]. They have been integrated into the human
genome multiple times after humans separated into races
and ethnic groups. Because they are present in poly-
morphisms among humans, are capable of producing
almost a complete repertoire of viral proteins, and have
a higher prevalence in certain human autoimmune dis-
eases, we analyzed for their presence among the study
populations.
Results
Table 1 shows the prevalence rates for anti-HERV-K10
Gag and Pol antibodies among the various subject popu-
lations. The LGLL patients (0%) had significantly lower
anti-HERV-K10 Gag seroprevalence rates than the VBD
(7%), suggesting that this peptide may not be the targetof the previously mentioned anti-HTLV p24 Gag re-
activity observed in LGLL patients. The anti-Gag reactiv-
ity of the VBD was not significantly different than that
observed in the HTLVn (7%) and MS subjects (11%).
However, the HTLVm patients had a significantly higher
seroprevalence rate (88%) than all the other groups. These
same relationships were maintained when one compares
the distributions of optical density or antibody titer for
anti-HERV-K10 Gag antibodies among the various popula-
tions (Figure 2, Figure 3).
Compared to the VBD (0%), LGLL (6%), HTLVt (28%),
HTLVm (94%), HTLVn (10%) and MS (16%) patients all
had a significantly higher seroprevalence for anti-HERV-
K10 Pol antibodies (Table 1). Again, these same relation-
ships held when the results were analyzed for optical
density or titer (Figure 4, Figure 5).
When analyzed for seropositivity against both (Gag
and Pol together) HERV-K10 peptides, all of the study
populations except the LGLL patients (0%) had a signifi-
cantly higher seroprevalence than the VBD (0%) (Table 2).
However, the HTLVm patients had a very high rate (82%),
which was significantly higher than the HTLVn subjects
(6.9%) and the MS patients (4.8%).
Among the HTLVm patients, 8 were HTLV-1 positive
and 8 were HTLV-2 positive. Six (75%) of the HTLV-2
positives had antibodies to both HERV-K10 peptides,
while all of the 8 (100%) HTLV-1 positives had anti-
bodies to the HERV-K10 Gag peptide, and 7 out of 8
(87.5%) had antibodies to HERV-K10 Pol peptide. Obvi-
ously, there were no significant differences in these results.
Among the 22 HTLV-1n subjects, 3 (13.6%) were reactive
to HERV-K10 Gag peptide, 3 (13.6%) were reactive to
HERV-K10 Pol peptide and these 3 (13.6%) were reactive
to both peptides. Among the 36 HTLV-2n subjects, 1
(2.8%) was reactive to HERV-K10 Gag, and 3 (8.3%)
were reactive to HERV-K10 Pol, with 1 (2.8%) being
Table 1 Prevalence of antibodies to HERV-K10 Gag and Pol peptides in different populations
VBD LGLL HTLVt HTLVm HTLVn MS
Peptides #tested #pos (%) #tested #pos (%) #tested #pos (%) #tested #pos (%) #tested #pos (%) #tested #pos (%)
HERV-K10 Gag* 100 7(7) 53 0(0) 74 18(24) 16 14(88) 58 4(7) 83 9(11)
HERV-K10 Pol+ 100 0(0) 53 3(6) 74 21(28) 16 15(94) 58 6(10) 83 13(16)
*HERV-K10 Gag VBD vs. LGLL, p = 0.047; VBD vs. all HTLV+, p = 0.001; VBD vs. HTLV +myelopathy, p = < 0.001: VBD vs. HTLV + non-myelopathy, p = 0.626; VBD vs.
multiple sclerosis, p = 0.256; HTLV +myelopathy vs. HTLV + non-myelopathy, p = <0.001; HTLV +myelopathy vs. MS p = < 0.001.
+HERV-K10 Pol VBD vs. LGLL, p = 0.040; VBD vs. all HTLV+, p = 0.001; VBD vs. HTLV +myelopathy, p = < 0.001: VBD vs. HTLV + non-myelopathy, p = 0.002; VBD vs.
multiple sclerosis, p = < 0.001; HTLV +myelopathy vs. HTLV + non-myelopathy, p = <0.001; HTLV +myelopathy vs. MS, p = < 0.001.
Perzova et al. Virology Journal 2013, 10:360 Page 3 of 7
http://www.virologyj.com/content/10/1/360reactive to both peptides. Again, these differences in
HERV-K10 seroprevalences between HTLV-1 and −2 in-
fected subjects were not statistically significant.
The mean OD minus background for the anti-HERV-
K10 Gag results among the HTLV-1 m patients was
0.841, while the same value for the HTLV-2 m patients
was 0.261 (p = 0.055). The mean titer for the anti-HERV-
K10 Gag results among the HTLV-1 m patients was 925,
while the same value for the HTLV-2 m patients was 250
(p = 0.129). The mean OD minus background for the anti-
HERV-K10 Pol results among the HTLV-1 m patients was
0.236, while the same value for the HTLV-2 m patients
was 0.125 (p = 0.072). The mean titer for the anti-HERV-
K10 Pol results among the HTLV-1 m patients was 325,
while the same value for the HTLV-2 m patients was 300
(p = 0.202).
Table 3 shows the prevalence of HERV-K113 and
HERV-K115 genomes among the various populations
studied. Seven subjects (6.7%) out of a total of 105 studied
were positive for HERV-K113, whereas 18 (17.1%) wereFigure 2 Distribution of optical density minus background
readings for the anti-HERV-K10 Gag peptide ELISA antibody
assay performed at a dilution of 1:200 among the various
subject populations. The horizontal bars represent the means for
each group and each dot represents one subject. Values below the
threshold for positive are shown at the bottom. The means for VBD,
LGLL, HTLVt, HTLVm, HTLVn and MS subjects were 0.027, 0, 0.142,
0.598, 0.016 and 0.017, respectively. VBD vs. LGLL, p = 0.002; VBD vs.
HTLVt, p = < 0.001; VBD vs. HTLVm, p = < 0.001; VBD vs. HTLVn,
p = < 0.001; VBD vs. MS, p = 0.331; HTLVm vs. HTLVn, p = < 0.001.positive for HERV-K115 (p = 0.001). The HTLVm patients
had a lower frequency of HERV-K113 or HERV-K115 (8%)
compared to the VBD (27%), but the difference was not
significant (p = 0.160). The HTLVn (27%), LGLL (33%)
and MS (33%) subjects had frequencies similar to the VBD.
Discussion
Increased risk for developing HAM is associated with
blood-borne viral transmission, increased proviral DNA
loads and anti-HTLV antibodies, polymorphisms in the
IL-10 promoter and IL-28B gene, HLA-A*02- and HLA-
DRB1*0101 alleles, and impaired anti-HTLV cytotoxic
T-cell responses [7,15-19]. There is no indication that
either HTLV-1 or HTLV-2 directly infects neuronal tissue.
Rather, it is assumed that the central nervous system is col-
laterally damaged by the anti-viral host immune response
[5,8,9]. Presumably, either direct immune system damage
or toxic effects of cytokines released in the immune
process injure the central nervous system. It would seem
plausible that anti-HTLV immunologic cross-reactivity to
epitopes within the cells of the central nervous system
could explain the tropism and cellular susceptibility to the
phenomenon. Indeed, molecular mimicry between HTLV-
1 Tax protein and neuron-specific ribonuclear antigen andFigure 3 Distribution of seropositive titers for the anti-HERV-K10
Gag peptide ELISA antibody assay among the various subject
populations. The means for VBD, LGLL, HTLVt, HTLVm, HTLVn and MS
subjects were 94, 0, 154, 613, 28, 101, respectively. VBD vs. LGLL,
p = 0.002; VBD vs. HTLVt, p = 0.002; VBD vs. HTLVm, p = < 0.001;
VBD vs. HTLVn, p = < 0.001; VBD vs. MS, p = 0.550; HTLVm vs.
HTLVn, p = < 0.001.
HERV-K10 Pol (457-469)
VBD       LGLL HTLVt HTLVm HTLVn     MS
Figure 4 Distribution of optical density minus background
readings for the anti-HERV-K10 Pol peptide ELISA antibody
assay performed at a dilution of 1:200 among the various
populations. The means for VBD, LGLL, HTLVt, HTLVm, HTLVn and MS
subjects were 0, 0.054, 0.037, 0.128, 0.004, 0.006, respectively. VBD vs.
LGLL, p = 0.041; VBD vs. HTLVt, p = < 0.001; VBD vs. HTLVm, p = < 0.001;
VBD vs. HTLVn, p = < 0.002; VBD vs. MS, p = < 0.001; HTLVm vs. HTLVn,
p = < 0.001.
Table 2 # of subjects in each population positive for both
anti-HERV K10 Gag & Pol antibodies







*p = 1.000, < 0.001, < 0.001, 0.017 and 0.041 for VBD vs LGLL, HTLVt, HTLVm;
HTLVn; and MS, respectively.
+p = < 0.001 for HTLVm vs HTLVn or vs MS.
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part of the pathogenesis of HAM [20].
It has been estimated that 8% of the human genome is
comprised of endogenous retroviral elements [21]. Most
of these are defective and transcriptionally inactive, but
many are capable of viral RNA and protein expression
[22-24]. If expressed prior to the ontogeny of the host
immune system, they would be recognized as “self”; if
subsequent to the formation of a competent immune
system, they would be recognized as “foreign” and a po-
tential cause of autoimmune diseases [24,25].HERV-K10 Pol (457-469)
VBD        LGLL     HTLVt HTLVm      HTLVn       MS
Figure 5 Distribution of seropositive titers for the anti-HERV-K10
Pol peptide ELISA antibody assay among the various subject
populations. The means for VBD, LGLL, HTLVt, HTLVm, HTLVn and MS
subjects were 0, 30, 84, 313, 21, 34, respectively. VBD vs. LGLL, p = 0.041;
VBD vs. HTLVt, p = < 0.001; VBD vs. HTLVm, p = < 0.001; VBD vs. HTLVn,
p = < 0.002; VBD vs. MS, p = < 0.001; HTLVm vs. HTLVn, p = < 0.001.HERV-K10 is a member of the HML-2 class of en-
dogenous retroviruses [26]. It has been shown to be
expressed in numerous human tissues including the cen-
tral nervous system; and it has been a suggested target
of autoimmune responses [27,28]. Such a hypothesis is
consistent with observations that increased expression of
HERV-K in HIV-1 infected patients leads to a cytotoxic
T-cell response toward HERV proteins [29-31]. Expres-
sion of HERV-K proteins and immune responses thereto
have been associated with a variety of human malignancies
and autoimmune diseases [32-34]. Further, the HTLV-1
Tax protein has been shown to transactivate HERV-K LTR
controlled transcription [35].
Our data indicate that, compared to VBD and HTLV +
non-myelopathy subjects, patients with HTLV myelop-
athy had higher titers of antibodies to two HERV-K10
peptides. This suggests that cross-reactive or direct im-
munity to HTLV-transactivated HERV-K expression in
the central nervous system could play a role in the
pathogenesis of HAM. Obviously, however, this data
alone would be insufficient to make such a case. If
HAM is associated with higher titers of anti-HTLV
antibodies, then it is quite possible that these patients
coincidentally would have higher antibody titers against
HTLV homologous HERV-K10 peptides. However, it is
indeed interesting that MS patients, who were HTLV
seronegative, also had a statistically significant higher










VBD 30 2(7) 6(20) 8(27)
LGLL 3 1(33) 0(0) 1(33)
HTVLt 24 0(0) 4(17) 4(17)
HTVLm 13 0(0) 1(8) 1(8)
HTVLn 11 0(0) 3(27) 3(27)
MS 24 4(17) 4(17) 8(33)
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indicate that broad anti-HERV-K Gag and Env-specific
T-cell responses were not detected in HTLV-I infected
subjects [28]. This would suggest that broad anti-HERV-K
immune responses may not be involved in the pathogen-
esis of HAM; but, it does not negate the possibility that
anti-HTLV immune responses, cross-reactive to select
HERV-K10 peptides, could. Further testing for a wider
range of anti-HERV-K10 immunoreactivity and HERV-




In an IRB-approved archival study, serum and peripheral
blood mononuclear cells (PBMC) were obtained from
100 VBD, 53 LGLL patients, 74 HTLV-1 or −2 infected in-
dividuals (HTLVt), 16 of whom had myelopathy (HTLVm)
(8 HTLV-1 and 8 HTLV-2), and 58 who did not (HTLVn)
(22 HTLV-1 and 36 HTLV-2), and 83 HTLV negative mul-
tiple sclerosis (MS) patients. All LGLL patients had clonal
T-cell lymphocytoses, as confirmed by PCR for clonal rear-
rangements of the T-cell receptor γ- gene and by positivity
for CD3, CD8, and CD57 proteins [36]. The HTLV myel-
opathy patients were all positive for either HTLV-1 or −2
antibodies and DNA in both their peripheral blood and
cerebrospinal fluid. They all manifested signs and symp-
toms of upper motor neuron disease, and met the updated
WHO criteria for HTLV myelopathy [37,38]. The MS pa-
tients were negative for HTLV-1 and −2 by serologic and
nucleic acid studies and fulfilled the McDonald diagnostic
criteria, which utilize both clinical and MRI findings [39].
Serologic studies
All subjects were screened for anti-HTLV antibodies
using a commercial HTLV1/2 EIA assay, as previously
described [40]. Seropositive individuals were further evalu-
ated using an HTLV-1/2 Western blot, as previously de-
scribed [41]. Sera were also tested for antibodies against
the HERV-K10 Pol peptide REPLENALTVFTD and the
HERV-K10 Gag peptide AYENANPECQ (Figure 1). Briefly,
the peptides were synthesized (New England Peptide LLC,
Gardner MA) and used to immunize rabbits. Pre- and post
immune rabbit sera were utilized as positive and negative
controls in an enzyme-linked immunoassay (ELISA). The
ELISA was performed as follows. The HERV-K10 peptide
was diluted in carbonate buffer, pH 9.6 (Sigma, St Louis,
MO) and 50 μl of solution containing 0.5 μg of peptide
was added to each well and incubated overnight at 4°C.
The wells were then washed five times with wash buffer
(1x PBS plus 0.2% Tween 20), and 100 μl of superblock
blocking buffer (Thermo Scientific, Hudson, NH) was
added to each well, incubated for 1 h at 37°C, and washed
five times with wash buffer. Then, 50 μl of the primaryantibody sample at the desired dilution in diluent buffer
was added to the well. A buffer only sample was used as a
background control. The samples were incubated for 1 h
at 37°C and, then washed five times with wash buffer. Goat
anti-rabbit (1:5000) or goat anti-human IgG-HRP (1:2000
in diluent buffer) (Sigma, Saint Louis, MO) was added and
incubated for 1 h at 37°C. Plates were then washed five
times, and 50 μl of hydrogen peroxide and tetramethylben-
zidine was added to each well and incubated for 10 min at
room temperature in the dark. The reaction was stopped
by the addition of 50 μl 1 N H2SO4 to each well and the
optical densities of the samples were read at 450 nm. A
sample was deemed positive if, at a dilution of 1:200, its
optical density was ≥ 2.5 x background plus 0.100 for the
Gag peptide or ≥ 2.5 x background for the Pol peptide.
Multiple permutations of the above conditions were con-
ducted using the pre- and post-immune rabbit sera and a
panel of three VBD sera as putative negative controls be-
fore settling on the above conditions. Positive samples were
then serially diluted and retested to determine their end
point titer.
PCR studies
DNA was extracted from serum or PBMC, and DNA in-
tegrity was confirmed by β-globin PCR, as previously de-
scribed [42]. Only samples that tested positive for human
β-globin at 0.1 μg and 1 μg of DNA input were deemed
suitable for subsequent retroviral DNA analysis. DNA was
analyzed for HTLV-1 and −2 DNA using the pol primers
SK110/SK111, the HTLV-1 pol probe SK-112, and the
HTLV-2 pol probe SK188, as previously described [42].
Quantification of HTLV viral load was done using real-
time PCR, as previously described [13].
The presence or absence of HERV-K113 and HERV-
K115 was determined with PCR primers spanning the
pre-integration sites and sites within the viral sequences.
The primers for HERV-K113 were those used by Moyes
et al. and those for HERV-K115 were used by Hughes
et al. [12,43]. Conditions for HERV-K113 were as de-
scribed and those for HERV-K115 were as provided by
Hughes et al. [43].
Statistics
Seroprevalence rates between various subject populations
were analyzed using Fisher’s t-test [44]. Comparisons of
serologic optical density scores and antibody titers were
analyzed using the contingency table method [44].
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